Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Steven F Russ"'
Autor:
Alison D Portnoy, Sanjay eKumar, David J Behm, Kelly M Mahr, Robert B Noble, John eThroup, Steven F Russ
Publikováno v:
Frontiers in Pharmacology, Vol 4 (2013)
Background: Urotensin II (U-II) is highly expressed in the human lung and has been implicated in regulating respiratory physiology in preclinical studies. Our objective was to test antagonism of the urotensin receptor (UT) by GSK1440115, a novel, com
Externí odkaz:
https://doaj.org/article/6464b7f4f5a54965914d203a037451d0
Autor:
Manisha Sahay, Kalpana S. Mehta, Georgi Abraham, Natalya A. Koziolova, Narina P. Alexeeva, Galina Y. Timokhovskaya, Robert G. Fassett, Elena V. Kolmakova, Elena A. Smolyarchuk, Alexey V. Borsukov, Kirill S. Lipatov, G P Arutyunov, Elena Zakharova, Tarun Kumar Saha, David K. Packham, Olga A. Zagrebelnaya, Coreen Oei, Steven F. Russ, Galina V. Volgina, Dmitry V. Perlin, Simon D. Roger, Vladimir A. Dobronravov, Vyacheslav V. Marasaev, Sanjay Kumar, Lawrence P. McMahon, Gullipalli Prasad, Dmitry A. Zateyshchikov, Lidia V. Lysenko, Brendan M. Johnson, Gordana Olbina, Bruce A. Cooper, Narinder Singh, Richard A. Brigandi, Mark Westerman, Janak de Zoysa, Veerabhadra Guptha, Nicholas B Cross
Publikováno v:
American journal of kidney diseases : the official journal of the National Kidney Foundation. 67(6)
Background Anemia associated with chronic kidney disease (CKD) often requires treatment with recombinant human erythropoietin (EPO). Hypoxia-inducible factor−prolyl hydroxylase inhibitors (PHIs) stimulate endogenous EPO synthesis and induce effecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e76f82129799128a19c1509d9c247637
https://pubmed.ncbi.nlm.nih.gov/26827289
https://pubmed.ncbi.nlm.nih.gov/26827289
Autor:
R. Noble, R. A. Brigandi, Steven F. Russ, Brendan M. Johnson, Peter Kranke, Leopold Eberhart, Jonathan P. Thompson, P. L. Dalby, E. Novikova
Publikováno v:
Survey of Anesthesiology. 59:185-186
Background Postoperative nausea and vomiting (PONV) is common; ondansetron is often used as prophylaxis or for breakthrough episodes. Vestipitant is a neurokinin 1 (NK-1) receptor antagonist that is effective for prophylaxis, but its efficacy for tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ace566f8ffc51a2cfc683da99c1bc6a
https://doi.org/10.1097/sa.0000000000000150
https://doi.org/10.1097/sa.0000000000000150
Autor:
Robert B. Noble, John P. Throup, Steven F. Russ, David J. Behm, Kelly M. Mahar, Sanjay Kumar, Alison Portnoy
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 4 (2013)
Frontiers in Pharmacology, Vol 4 (2013)
Background: Urotensin II (U-II) is highly expressed in the human lung and has been implicated in regulating respiratory physiology in preclinical studies. Our objective was to test antagonism of the urotensin receptor (UT) by GSK1440115, a novel, com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee2594e9adff7e11804f5c0db33fd402
http://europepmc.org/articles/PMC3638148
http://europepmc.org/articles/PMC3638148